StreetInsider.com News Articles

Form 6-K Clearmind Medicine Inc. For: Jul 20

Mon, 20 Jul 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260720/26789613.html

Form 6-K Clearmind Medicine Inc. For: Jul 20

Mon, 20 Jul 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260720/26789613.html

Clearmind Medicine files Hong Kong patent for PTSD compounds

Mon, 20 Jul 2026 07:55:21 -0400

Clearmind Medicine Inc. (NASDAQ: CMND) has filed a patent application with the Hong Kong Patent Office covering psychedelic compounds intended for the treatment of Post-Traumatic Stress Disorder and other mental health disorders, according to a company statement.

The Hong Kong filing is part of Clearmind's exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. Under that agreement, Clearmind holds exclusive global rights to develop, manufacture, and commercialize novel compounds developed at Yissum.

The company said the Hong Kong application adds to existing patent coverage in the United States, Europe, and other jurisdictions. Clearmind's intellectual property portfolio

Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market

Mon, 20 Jul 2026 07:55:00 -0400

Vancouver, Canada, July 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogen-derived treatments for Alcohol Use Disorder (“AUD”), addiction, and weight management, today announced the filing of a patent application with the Hong Kong Patent Office for innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder (“PTSD”) and other mental health disorders.

The Hong Kong patent application forms part of Clearmind’s exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”). Under the terms of the licensing agreement,

Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market

Mon, 20 Jul 2026 07:55:00 -0400

Form 6-K Clearmind Medicine Inc. For: Jul 17

Fri, 17 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260717/26784267.html

Form 6-K Clearmind Medicine Inc. For: Jul 17

Fri, 17 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260717/26784267.html

FDA issues psychedelic therapy guidance as Clearmind notes federal push

Fri, 17 Jul 2026 07:32:55 -0400

Clearmind Medicine Inc. (NASDAQ: CMND), a clinical-stage biotechnology company, issued a statement acknowledging recent U.S. federal regulatory developments related to psychedelic-based therapies for mental health and addiction treatment.

The developments include final FDA guidance on psychedelic clinical investigations, a planned public hearing on the therapeutic use of psychedelics, and new Memoranda of Understanding involving the U.S. Department of Health and Human Services, the Department of Veterans Affairs, the FDA, the National Institute on Drug Abuse, ARPA-H, and the Health Resources and Services Administration.

Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, said: "At a time when patients in the veterans community and the

FDA issues psychedelic therapy guidance as Clearmind notes federal push

Fri, 17 Jul 2026 07:32:55 -0400

Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, said: "At a time when patients in the veterans community and the

Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction

Fri, 17 Jul 2026 07:32:00 -0400

Vancouver, Canada, July 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, today noted the significant regulatory and inter-agency developments this week supporting the development of innovative treatments for serious neuropsychiatric and addiction disorders.

Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, stated: “At a time when patients in the veterans community and the general population have too few treatment options for intractable neuropsychiatric and addiction disorders, we are grateful that Secretary Kennedy is looking to transform treatment opportunities

Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction

Fri, 17 Jul 2026 07:32:00 -0400

Form 6-K Clearmind Medicine Inc. For: Jul 16

Thu, 16 Jul 2026 13:39:00 -0400

si-local-file:///var/storage/secattach/20260716/26778928.html

Form 6-K Clearmind Medicine Inc. For: Jul 16

Thu, 16 Jul 2026 13:39:00 -0400

si-local-file:///var/storage/secattach/20260716/26778928.html

Clearmind reports improved nasal retention for its MEAI drug formulation

Thu, 16 Jul 2026 09:30:27 -0400

Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company, announced results from an ex vivo mucoadhesion study showing its intranasal formulation of MEAI (5-Methoxy-2-aminoindane) retained a greater proportion of its dose on nasal tissue compared to a standard MEAI solution.

The study used freshly isolated rabbit nasal mucosa to evaluate how well the intranasal formulation adhered to nasal tissue over a 30-minute period. Both formulations were applied to tissue and exposed to a simulated nasal electrolyte solution. The intranasal MEAI formulation maintained a higher proportion of its initially adhered dose throughout the evaluation period compared to the non-mucoadhesive reference solution.

The company

Clearmind reports improved nasal retention for its MEAI drug formulation

Thu, 16 Jul 2026 09:30:27 -0400

The company

Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI

Thu, 16 Jul 2026 09:30:00 -0400

Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering non‑hallucinogenic neuroplastogen‑derived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, announced today compelling ex vivo mucoadhesion results for its intranasal formulation of MEAI (5‑Methoxy‑2‑aminoindane). Leveraging a nasal drug‑delivery system, the new formulation demonstrated markedly improved nasal residence characteristics compared with a standard MEAI solution.

Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potential. These results reinforce Clearmind’s strategy of developing differentiated, next‑generation treatments for AUD and other high‑need indications.

The

Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI

Thu, 16 Jul 2026 09:30:00 -0400

The

Form 6-K Clearmind Medicine Inc. For: Jul 13

Mon, 13 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260713/26762399.html

Form 6-K Clearmind Medicine Inc. For: Jul 13

Mon, 13 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260713/26762399.html

Clearmind reports early safety data from CMND-100 alcohol disorder trial

Mon, 13 Jul 2026 08:17:50 -0400

Clearmind Medicine Inc. (NASDAQ: CMND), a clinical-stage biotech company, shared early observations from its ongoing Phase I/IIa first-in-human trial of CMND-100, a non-hallucinogenic compound being studied as a treatment for alcohol use disorder (AUD).

The update, drawn from a June 10 webinar titled "Inside MEAI," featured remarks from two principal investigators: Dr. Anahita Bassir Nia of Yale School of Medicine and Dr. Jennifer Ellis of Johns Hopkins University. Both described a generally positive early impression of CMND-100 based on their experience in the trial to date.

Key observations shared by the investigators included a promising early safety profile, with no meaningful adverse

Clearmind reports early safety data from CMND-100 alcohol disorder trial

Mon, 13 Jul 2026 08:17:50 -0400

Key observations shared by the investigators included a promising early safety profile, with no meaningful adverse

Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial

Mon, 13 Jul 2026 08:17:00 -0400

Principal Investigators of the Ongoing Phase I/II a Trial Highlighted Positive Early Experience with Clearmind Medicine’s Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder

Vancouver, Canada, July 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today provides key insights from its June 10 webinar, “Inside MEAI,” during which the Company’s CEO and the leading investigators of the Company’s ongoing first-in-human clinical trial of CMND-100 (the “Trial”), provided an update based

Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial

Mon, 13 Jul 2026 08:17:00 -0400

Principal Investigators of the Ongoing Phase I/II a Trial Highlighted Positive Early Experience with Clearmind Medicine’s Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder

Form 6-K Clearmind Medicine Inc. For: Jul 10

Fri, 10 Jul 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260710/26757292.html

Form 6-K Clearmind Medicine Inc. For: Jul 10

Fri, 10 Jul 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260710/26757292.html